Skip to main content

Animations

Thomas McCown, PhD

Research Professor of Psychiatry at University of North Carolina at Chapel Hill

Location: Chapel Hill, NC United States

Over the last 15 years, the McCown laboratory has focused upon the development of safe, effective gene therapies for the treatment of epilepsy.  Over these years we have developed a novel gene therapy platform where inhibitory neuroactive peptides could be expressed and constitutively secreted from AAV transduced neurons.  This novel platform has proven capable of blocking both electrographic and behavioral limbic seizures.  In addition, we have developed a means to create novel AAV vectors that upon peripheral administration, selectively cross the seizure compromised blood brain barrier but do not cross the intact blood-brain barrier.  The ability of these hybrid adeno-associated virus vectors to selectively target areas of brain pathology could radically shift the application of viral vector gene therapy, not only for the epilepsies but also other neurological disorders that compromise the blood brain barrier, such as Parkinson’s disease.


Associated Grants

  • The Development of Novel Adeno-associated Virus Vectors for Intravenous Parkinson's Gene Therapy

    2011


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.